- Home
- QURE vs KRYS Comparison
QURE vs KRYS Comparison
Compare QURE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- KRYS
- Stock Information
- Founded
- QURE 1998
- KRYS 2015
- Country
- QURE Netherlands
- KRYS United States
- Employees
- QURE N/A
- KRYS N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QURE Health Care
- KRYS Health Care
- Exchange
- QURE Nasdaq
- KRYS Nasdaq
- Market Cap
- QURE 4.3B
- KRYS 4.7B
- IPO Year
- QURE 2007
- KRYS 2017
- Fundamental
- Price
- QURE $30.76
- KRYS $207.89
- Analyst Decision
- QURE Strong Buy
- KRYS Strong Buy
- Analyst Count
- QURE 13
- KRYS 9
- Target Price
- QURE $62.33
- KRYS $214.22
- AVG Volume (30 Days)
- QURE 4.6M
- KRYS 326.5K
- Earning Date
- QURE 11-10-2025
- KRYS 11-03-2025
- Dividend Yield
- QURE N/A
- KRYS N/A
- EPS Growth
- QURE N/A
- KRYS 275.72
- EPS
- QURE N/A
- KRYS 6.66
- Revenue
- QURE $15,751,000.00
- KRYS $373,164,000.00
- Revenue This Year
- QURE N/A
- KRYS $34.33
- Revenue Next Year
- QURE $229.18
- KRYS $48.04
- P/E Ratio
- QURE N/A
- KRYS $31.35
- Revenue Growth
- QURE N/A
- KRYS 54.51
- 52 Week Low
- QURE $5.50
- KRYS $122.80
- 52 Week High
- QURE $71.50
- KRYS $212.98
- Technical
- Relative Strength Index (RSI)
- QURE 36.57
- KRYS 70.35
- Support Level
- QURE $25.24
- KRYS $198.02
- Resistance Level
- QURE $31.16
- KRYS $209.96
- Average True Range (ATR)
- QURE 3.74
- KRYS 8.66
- MACD
- QURE -2.28
- KRYS 0.27
- Stochastic Oscillator
- QURE 16.43
- KRYS 87.11
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.